Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
181/433
Matches for
“Biomarker”
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication
…As waiting for the perfect biomarker for the diagnosis of advanced fibrosis…
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Biomarkers of liver fibrosis.
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
…The biomarker data were obtained, and patients with presumed advanced fibrosis were…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
…Furthermore, NAFLD diagnosis relied exclusively on circulating biomarker-based liver scores, without…
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
…Conclusion FibroTest is a validated biomarker for the prognosis of patients with…
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
…Scores from four biomarker tests, FibroTest, APRI, FIB-4 and Forns' Score…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.
…study identifies 20 novel fibrosis biomarker candidates. The proteins identified may help…
-
The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…
-
Non-invasive markers for hepatic fibrosis.
…Current non-invasive methods range from serum biomarker assays to advanced imaging…
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
…Although clinically useful, current biomarker predictions may be influenced by hepatic and…
-
FibroMAX: towards a new universal biomarker of liver disease?
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
…This technology yielded a biomarker that distinguished compensated cirrhotic from noncirrhotic chronic…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
…The most thoroughly evaluated biomarker is the FibroTest (FT) (AUROC 0.80…
-
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.
-
Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.
### Background And Aims Hepatobiliary disorders, associated either with extraintestinal manifestations or with…
-
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
### Background Two widely used biomarkers of fibrosis, FibroTest and liver stiffness measurement…
-
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable?
…However, its applicability is lower (80%) than that of serum biomarker (particularly…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
…The recommendation for biopsy analysis, instead of a validated biomarker panel such…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
Optimization and robustness of blood tests for liver fibrosis and cirrhosis.
### Objectives To optimize the performance and feasibility of fibrosis blood tests and…
-
Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
FibroTest has been validated as a biomarker of fibrosis in patients with…
-
Liver biopsy: the best standard...when everything else fails.
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.
### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
### Background Liver biopsy and virological end points are standard references for assessing…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
### Background No blood test has been shown to be effective in the…
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
Biomarkers for liver disease in urea cycle disorders.
### Background Urea cycle disorders (UCDs) are among the most common inborn errors…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
…combination of 4 non-invasive biomarker panels for the diagnosis of steatosis…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
…and a competitor as a biomarker of liver fibrosis in comparison with…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
### Background Liver biopsy is considered as the gold standard for assessing non…
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the…
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
### Background Although the FibroTest has been validated as a biomarker to determine…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
…Using biopsy as reference, FibroTest™ has been validated as a biomarker of…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
### Background/Aims The hepatitis C virus (HCV) infection is important cause of…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
### Background Blood tests of liver injury are less well validated in non…
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
…assessed by a non invasive biomarker (Fibrotest), was evaluated first, by a…
-
Screening studies of transient elastography and FibroTest in the general population - Authors' reply.
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…
-
Noninvasive evaluation of NAFLD.
A common clinical concern in patients with NAFLD is whether they have…
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
### Background The Fib-4 index is a simple and inexpensive biomarker to…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.
…valuable and easy-to-use biomarker for predicting the risk of worsening…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
…of body mass index, and biomarker parameters in serum using FibroMax. ### Results…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
### Background There is a clear need for better biomarkers of drug-induced…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
…The aim was to develop and validate a new biomarker of non…
-
Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.
### Background The prediction of fibrosis is an essential part of the assessment…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.
### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
### Background And Aims The PGAA index was one of the first composite…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
…for the evaluation of serum biomarker performance. The AUROCs of the Fibrotest…
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
…and resistin; and the noninvasive biomarker SteatoTest and anthropometric evaluations. A semiquantitative…
-
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).
### Background & Aims The diagnostic accuracy of non-invasive liver fibrosis tests that…
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
### Context Recently, it has been shown that an allele in the adiponutrin…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
### Background The combination of transaminases (ALT), biopsy, HBeAg and viral load have…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
### Background & Aims Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic liver…
-
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.
Liver fibrosis is currently assessed by liver biopsy, a costly and rather…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.
Non-invasive modalities to estimate fibrosis stage are desirable in hepatitis C…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
### Background No blood test has been shown to be effective in the…
-
Effective use of FibroTest to generate decision trees in hepatitis C.
### Aim To assess the usefulness of FibroTest to forecast scores by constructing…
-
Liver fibrosis markers in alcoholic liver disease.
Alcohol is one of the main factors of liver damage. The evaluation…
-
Screening studies of transient elastography and FibroTest in the general population.
-
Poynard T, Ratziu V, Imbert-Bismut F, Munteanu M
-
Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…
-
Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J, Benhamou Y
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.
### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk…
-
Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.
### Objectives Personalized ranges of liver fibrosis serum biomarkers such as FibroTest or…
-
Applicability and variability of liver stiffness measurements according to probe position.
### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Non-invasive assessment of liver fibrosis: are we ready?
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…
-
Altered serum N-glycomics in chronic hepatitis B patients.
### Background We previously reported on serum N-glycans as markers for the…
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…
-
Molecular characteristics of Hepatitis B and chronic liver disease in a cohort of HB carriers from Bamako, Mali.
### Background Hepatitis B (HB) infection is common in Mali. However, there is…
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
### Background & Aims Real-time shear wave elastography (SWE) is a new two…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
### Background/Aims The aim was to identify a panel of biomarkers (AshTest…
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
…FibroTest is a non-invasive biomarker assay for fibrosis, proposed as a…
-
[Prognosis assessment of alcoholic liver disease: how and why?].
…Non-invasive methods such as biomarker tests (e.g. FibroTest(®) or FibroMetre…
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
In this article, we comment on the article by Peta _et al…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.
…FibroTest® could be a relevant biomarker of coronary calcification and cardiovascular risk…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
### Background One of the unmet needs in patients with metabolic risks is…
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
### Background This prospective, monocentric study was designed to assess the efficacy of…
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.
### Background Noninvasive tests are crucial for the management and follow-up of…
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.
### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…
-
Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.
Barriers to management of HCV in injection drug users are related to…
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
### Background & Aims Liver stiffness can be measured noninvasively to assess liver fibrosis…
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
Therapeutic options in hepatitis C virus (HCV)-related vasculitis may target the…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
### Background And Aims Gilbert syndrome (GS) is genotypically predetermined by UGT1A1*28…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
### Objective There is a controversy about the performance of blood tests for…
-
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
### Introduction Identifying liver fibrosis is important to evaluate the severity of liver…
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
### Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common…
-
Noninvasive diagnosis in alcohol-related liver disease. Review
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.
### Aim Of The Study Was to evaluate liver disease severity in children…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
Owing to the high prevalence of various chronic liver diseases, cirrhosis is…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
### Aims To evaluate the application of the recently proposed recommendations by the…
-
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…
-
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.
### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…
-
Usefulness of acoustic radiation force impulse and fibrotest in liver fibrosis assessment after liver transplant.
### Unlabelled Background and rationale. Acoustic radiation force impulse (ARFI) is a non…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis.
### Objectives Extent of liver fibrosis is one of the most important factors…
-
Noninvasive Assessment of Liver Fibrosis.
### Background The prognosis and management of chronic liver diseases greatly depend on…
-
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
Fontan-associated liver disease (FALD) is a serious complication related to the…
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…
-
Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.
### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…
-
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis.
### Background Acoustic radiation force impulse (ARFI) imaging is a new non-invasive…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.
### Aim The objective of this study was to evaluate liver fibrosis using…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…
-
Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics.
Fontan-palliated patients are at risk for the development of Fontan-associated…
-
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…
-
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.
### Background Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly…
-
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…
-
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
### Background The area under the receiver operating characteristic (ROC) curve is widely…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.
### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
### Objective Nonalcoholic steatohepatitis (NASH) has become a prominent liver disease in contemporary…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
### Background Liver stiffness and non-invasive tests predict overall survival in chronic…
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…
-
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…
-
Noninvasive assessment of portal hypertension in patients with cirrhosis.
Severe portal hypertension is responsible for complications and death. Although measurement of…
-
Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.
### Background Previous research has shown variation in the effects of patient factors…
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.
The assessment of the fibrotic evolution of chronic hepatitis has always been…
-
Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B.
### Background & Aims Data on liver fibrosis evolution and its involvement in liver…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection.
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
**Background/Objectives**: Prior research has identified a significant association between heart disease…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
### Background One of the unmet needs in patients with type 2 diabetes…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages].
Liver cirrhosis in Mexico is one of the most important causes of…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…
-
Non-invasive diagnosis of hepatitis B virus-related cirrhosis.
Chronic hepatitis B (CHB) infection is a major public health problem associated…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
Showing the full result list. The page is server-rendered and not paginated.